Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Kun Run Reports Strong 2008 Results

publication date: Apr 1, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Kun Run Biotechnology, a company that focuses on peptide-based drugs, reported that 2008 revenues climbed 56% to $11.6 million. Net income nearly tripled from the year earlier, rising to $6 million or 52% of sales on a non-GAAP basis. Earnings per share were 24 cents, fully diluted. The $6 million net income number includes a $2.4 million extraordinary gain from the sale of property, and also reflects a one-time charge for a Make-Good Provision, which reduced earnings by $1.3 million. More details...

Stock Symbol: (OTCBB: KURU)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...